文献速递心外重症与机械循环支持

Impella RP 装置短期血流动力学支持治疗右心衰竭的结局

Outcomes of patients with right ventricular failure requiring short-term hemodynamic support with the Impella RP device.
PubMed 文献 · J Heart Lung Transplant · 2018-08-08

装置支持后血流动力学立即改善,心脏指数从 1.9±0.1 升至 3.1±0.2 L/min/m²(p<0.001),30 天或出院生存率为 72%。

要点

  • Impella RP 支持后心脏指数立即升高、中心静脉压下降。
  • 30 天或出院总体生存率为 72%。
  • 研究为迄今最大规模的前瞻性严重右心衰竭研究。

核心结论

  • Impella RP 装置为严重右心衰竭患者提供机械支持,可快速改善血流动力学并逆转休克,生存率良好。

研究设计与样本

  • 研究人群分两组:A 组为 LVAD 植入后右心衰竭(n=31),B 组为心脏术后、心脏移植或心肌梗死后右心衰竭(n=29)。

主要发现

  • 患者平均年龄 59±15 岁,68% 为男性,84% 有充血性心力衰竭病史,44% 有瓣膜病,35% 有术前肾功能不全。
  • Impella RP 植入前平均使用 3.4 种正性肌力药/血管升压药。
  • 装置支持时间为 4.0±1.5 天(范围 0.5 至 14 天)。
  • 装置启动后血流动力学立即改善:心脏指数从 1.9±0.1 升至 3.1±0.2 L/min/m²(p<0.001),中心静脉压从 19.0±1 降至 13±1 mm Hg(p<0.001)。
  • 30 天(或出院)总体生存率为 72%。

临床怎么用

  • 对于药物治疗无效的严重右心衰竭(心梗后、心脏术后或 LVAD 植入后),可考虑使用 Impella RP 装置进行短期机械循环支持以快速稳定血流动力学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Right ventricular failure (RVF) after myocardial infarction, cardiotomy, or left ventricular assist device (LVAD) implantation increases morbidity and mortality. RVF also contributes to prolonged length of hospital stay and higher costs of care. The aim of this study was to evaluate the efficacy and safety of the Impella RP (Abiomed, Danvers, MA) in patients with severe RVF in these clinical settings. METHODS: This is a prospective cohort study of patients with severe RVF treated with a percutaneous right ventricular assist device (RVAD). Sixty patients with RVF refractory to medical treatment received the Impella RP device at 14 United States institutions as part of the Impella RP pre‒ and post‒market approval studies. The study population included 2 cohorts: Cohort A, patients with RVF post-(LVAD) implantation (n = 31); and Cohort B, patients with RVF post-cardiotomy, heart transplant, or myocardial infarction (n = 29). The primary end-point was survival at 30 days or hospital discharge (whichever was longer). RESULTS: Mean age of patients was 59 ± 15 years; 68% were males, 84% had a history of congestive heart failure, 44% had valvular disease, and 35% had pre-operative renal dysfunction. Patients received an average of 3.4 inotropes/vasopressors before the Impella RP implant. Patients were supported with the Impella RP for 4.0 ± 1.5 (0.5 to 14) days. Hemodynamics improved immediately after initiation of device support, with an increase in cardiac index from 1.9 ± 0.1 to 3.1 ± 0.2 liters/min/m2 (p < 0.001) and a decrease in central venous pressure from 19.0 ± 1 to 13 ± 1 mm Hg (p < 0.001). The overall survival at 30 days (or discharge) was 72%. CONCLUSIONS: To the best of our knowledge, this study represents the largest prospective study of patients with life-threatening RVF. Mechanical support with the Impella RP device in patients with RVF resulted in rapid hemodynamic improvement with reversal of shock and favorable survival.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Anderson M, Morris DL, Tang D, et al. Outcomes of patients with right ventricular failure requiring short-term hemodynamic support with the Impella RP device. J Heart Lung Transplant. 2018. PMID: 30241890. doi:10.1016/j.healun.2018.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。